期刊文献+

基于假病毒的高通量人类免疫缺陷病毒表型耐药性检测方法的建立和优化 被引量:2

Establishment and optimization of a high throughput phenotypic test for the detection of drug resist-ance in human immunodeficiency virus(HIV)strains
原文传递
导出
摘要 目的:建立一种高通量人类免疫缺陷病毒表型耐药性检测方法。方法通过酶切连接方式失活荧光素酶基因,用LacZ基因替代原有的蛋白酶和逆转录酶基因。通过PCR方法从含耐药基因的pSG3△env质粒中扩增pol基因,用infusion定向克隆技术连接入酶切后的pNL4-3.Lac,对该表型耐药性检测方法的主要影响因素进行优化。结果构建了用于高通量耐药性检测的pNL4-3.Lac,确定了检测方法中细胞加入量为10000细胞/孔(96孔板),病毒加入量为200 TCID 50/孔,DEAE-dextran的最佳工作浓度为15μg/ml。用12种抗病毒药物检测两种假病毒8次,确定方法具有良好的重复性(CV值在4.32%~28.46%之间)。构建了6种不同的假病毒与基于pSG3△env的耐药性检测方法进行比较,两者之间具有良好的一致性。结论基于pNL4-3.Lac的表型耐药性检测方法结合了pSG3△env和pNL4-3检测系统的优点,能高通量评价HIV病毒对药物的耐受性,可用于感染者耐药性分析和抗病毒药物的筛选。 Objective To establish a high throughput phenotypic test for the detection of drug resistance in human immunodeficiency virus(HIV)strains. Methods The gene encoding luciferase was inactivated through restriction enzyme digestion and ligation. LacZ gene was used to replace the genes encoding original protease and reverse transcriptase. pol genes were amplified from pSG3△env plasmid and cloned into a new backbone plasmid through infusion. The factors that might affect the results of the test were optimized. Results The parental backbone plasmid pNL4-3. Lac was constructed,of which the gene encoding luciferase was inactivated and bearing the LacZ gene instead of genes encoding protease and reverse transcriptase. Several influential factors including cell numbers(10 000 / well),virus inoculation(200 TCID50 /well)and the concentration of DEAE-dextran(15 μg/ ml)were optimized. The reproducibility of this test was confirmed by testing 12 anti-HIV drugs against 2 pseudovirus strains 8 times,presenting the coefficient of variations(CVs)from 4. 32% to 28. 46% . Six types of pseudovirus were constructed and tested against the 12 anti-HIV drugs,the results of which were compared with those by using the pSG3△env-based pseudovirus test. The results of the two tests presented good consistency. Conclusion The high throughput phenotypic test based on pNL4-3. Lac plasmid,combining the advantages of pSG3△env and pNL4-3 systems, could be used to analyze the drug resistance patterns of HIV-1 infectors and screen new drugs for antiretroviral therapy in a rapid and effective way.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2014年第12期941-949,共9页 Chinese Journal of Microbiology and Immunology
基金 “重大传染病防治”国家科技重大专项(2012ZX10004701-001) 中国食品药品检定研究院中青年发展研究基金(2012B2)
关键词 人类免疫缺陷病毒 耐药性 表型检测 Human immunodeficiency virus Drug resistance Phenotypic test
  • 相关文献

参考文献27

  • 1The Joint United Nations Programme on HIV/AIDS. UNAIDS re- port on the global AIDS epidemic 2013 [ M]. Geneva: UNAIDS, 2013.
  • 2Suguimoto SP, Techasrivichien T, Musumari PM, et al. Changing patterns of HIV epidemic in 30 years in East Asia[J]. Curr HIV/ AIDS Rep, 2014, 11(2) : 134-145.
  • 3Chow EP, Lau JT, Zhuang X, et al. HIV prevalence trends, risky behaviours, and governmental and community responses to the epi- demic among men who have sex with men in China[ J]. Biomed Res Int, 2014, 2014: 607261.
  • 4Chabria SB, Gupta S, Kozal MJ. Deep sequencing of HIV: clini- cal and research applications [ J ]. Annu Rev Genomics Hum Gen- et, 2014, 15: 295-325.
  • 5Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-I across the world[J]. AIDS Rev, 2012, 14(1) : 17-27.
  • 6Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiret- roviral resistance in treatment-naive individuals with HIV after roll- out of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis [ J ]. Lancet, 2012, 380(9849) : 1250-1258.
  • 7Hang SY, Nachega JB, Kelley K, et al. The global status of HIV drug resistance: clinical and public-health approaches for detec- tion, treatment and prevention [ J ]. Infect Disord Drug Targets, 2011, 11(2): 124-133.
  • 8Prosperi MC, Mackie N, Di Giambenedetto S, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a Eu- ropean multicentre cohort study [ J 1. J Antimicrob Chemother, 2011, 66(8) : 1886-1896.
  • 9van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis [ J ]. Curr Opin Infect Dis, 2010, 23(6) : 621-627.
  • 10World Health Organization. WHO HIV drug resistance report 2012 [M]. Geneva: WHO, 2012.

二级参考文献5

  • 1Ho DD. Time to hit HIV, early and hard. N Engl J Med, 1995,333 (7) :450
  • 2Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphoeytes in HIV - 1 infection. Nature, 1995,6510 (373) :123
  • 3Petropoulos C J, Parkin NT, Limoli KL,et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2000,44 ( 4 ) : 920
  • 4Garcia - Perez J, Sanchez - Palomino S, Perez - Olmeda M, et al. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol , 2007,79(2) :127
  • 5Paolucci S, Baldanti F, Zavattoni M, et al. Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations con- ferring drug resistance to HIV - 1 variants. J Antimicrob Chemother, 2004,53 ( 5 ) :766

共引文献7

同被引文献29

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部